Generic placeholder image

Current Vascular Pharmacology

Author(s): Andrej Janez, Rok Herman, Pavel Poredos, Dimitri P. Mikhailidis, Ales Blinc, Miso Sabovic, Katica Bajuk Studen, Mateja Kaja Jezovnik, Gerit-Holger Schernthaner, Panagiotis Anagnostis, Pier Luigi Antignani and Mojca Jensterle*

DOI: 10.2174/0115701611269146230920073301

DownloadDownload PDF Flyer Cite As
Cardiometabolic Risk, Peripheral Arterial Disease and Cardiovascular Events in Polycystic Ovary Syndrome: Time to Implement Systematic Screening and Update the Management

Page: [424 - 432] Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

Polycystic ovary syndrome (PCOS) is a highly prevalent endocrine disorder in women of reproductive age. It presents with gynaecologic, metabolic, and psychologic manifestations. The dominant drivers of pathophysiology are hyperandrogenism and insulin resistance. Both conditions are related to cardiometabolic risk factors, such as obesity, hypertension, dyslipidaemia, hyperglycaemia, type 2 and gestational diabetes, nonalcoholic fatty liver disease and obstructive sleep apnoea. Women with PCOS of reproductive age consistently demonstrated an elevated risk of subclinical atherosclerosis, as indicated by different measurement methods, while findings for menopausal age groups exhibited mixed results. Translation of subclinical atherosclerosis into the increased incidence of peripheral arterial disease and major cardiovascular (CV) events is less clear. Although several expert groups have advised screening, the CV risk assessment and prevention of CV events are frequently underdiagnosed and overlooked aspects of the management of PCOS. A combination of lifestyle management and pharmacotherapy, including the promising new era of anti-obesity medicine, can lead to improvements in cardiometabolic health.

Graphical Abstract

[1]
Guan C, Zahid S, Minhas AS, et al. Polycystic ovary syndrome: A “risk-enhancing” factor for cardiovascular disease. Fertil Steril 2022; 117(5): 924-35.
[http://dx.doi.org/10.1016/j.fertnstert.2022.03.009] [PMID: 35512976]
[2]
Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19(1): 41-7.
[http://dx.doi.org/10.1093/humrep/deh098] [PMID: 14688154]
[3]
Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab 2023; dgad463.
[http://dx.doi.org/10.1210/clinem/dgad463] [PMID: 37580314]
[4]
Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism 2019; 92: 108-20.
[http://dx.doi.org/10.1016/j.metabol.2018.11.002] [PMID: 30445140]
[5]
Lentscher JA, Decherney AH. Clinical presentation and diagnosis of polycystic ovarian syndrome. Clin Obstet Gynecol 2021; 64(1): 3-11.
[http://dx.doi.org/10.1097/GRF.0000000000000563] [PMID: 32701517]
[6]
Louwers YV, Laven JSE. Characteristics of polycystic ovary syndrome throughout life. Therap Adv Reprod Heal 2020; p. 14.
[http://dx.doi.org/10.1177/2633494120911038] [PMID: 32518918]
[7]
Mo L, Mansfield DR, Joham A, et al. Sleep disturbances in women with and without polycystic ovary syndrome in an Australian National Cohort. Clin Endocrinol 2019; 90(4): 570-8.
[http://dx.doi.org/10.1111/cen.13922] [PMID: 30585648]
[8]
Lim SS, Kakoly NS, Tan JWJ, et al. Metabolic syndrome in polycystic ovary syndrome: A systematic review, meta-analysis and meta-regression. Obes Rev 2019; 20(2): 339-52.
[http://dx.doi.org/10.1111/obr.12762] [PMID: 30339316]
[9]
Sarkar M, Terrault N, Chan W, et al. Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis. Liver Int 2020; 40(2): 355-9.
[http://dx.doi.org/10.1111/liv.14279] [PMID: 31627243]
[10]
Hudnut-Beumler J, Kaar JL, Taylor A, et al. Development of type 2 diabetes in adolescent girls with polycystic ovary syndrome and obesity. Pediatr Diabetes 2021; 22(5): 699-706.
[http://dx.doi.org/10.1111/pedi.13206] [PMID: 33870630]
[11]
Simon S, Rahat H, Carreau AM, et al. Poor sleep is related to metabolic syndrome severity in adolescents with pcos and obesity. J Clin Endocrinol Metab 2020; 105(4): e1827-34.
[http://dx.doi.org/10.1210/clinem/dgz285] [PMID: 31901092]
[12]
Legro R. Obesity and PCOS: Implications for diagnosis and treatment. Semin Reprod Med 2012; 30(6): 496-506.
[http://dx.doi.org/10.1055/s-0032-1328878] [PMID: 23074008]
[13]
Tao Y, Liu B, Chen Y, et al. Genetically predicted cigarette smoking in relation to risk of polycystic ovary syndrome. Clin Epidemiol 2021; 13: 527-32.
[http://dx.doi.org/10.2147/CLEP.S311785] [PMID: 34239329]
[14]
Pau CT, Keefe CC, Welt CK. Cigarette smoking, nicotine levels and increased risk for metabolic syndrome in women with polycystic ovary syndrome. Gynecol Endocrinol 2013; 29(6): 551-5.
[http://dx.doi.org/10.3109/09513590.2013.788634] [PMID: 23656383]
[15]
Cupisti S, Häberle L, Dittrich R, et al. Smoking is associated with increased free testosterone and fasting insulin levels in women with polycystic ovary syndrome, resulting in aggravated insulin resistance. Fertil Steril 2010; 94(2): 673-7.
[http://dx.doi.org/10.1016/j.fertnstert.2009.03.062] [PMID: 19394003]
[16]
Kakoly NS, Earnest A, Teede HJ, Moran LJ, Joham AE. The impact of obesity on the incidence of type 2 diabetes among women with poly-cystic ovary syndrome. Diabetes Care 2019; 42(4): 560-7.
[http://dx.doi.org/10.2337/dc18-1738] [PMID: 30705063]
[17]
Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: Systematic review and meta-analysis. Fertil Steril 2011; 95(3): 1073-1079.e11, 11.
[http://dx.doi.org/10.1016/j.fertnstert.2010.12.027] [PMID: 21247558]
[18]
Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol 1992; 37(2): 119-25.
[http://dx.doi.org/10.1111/j.1365-2265.1992.tb02295.x] [PMID: 1395062]
[19]
National cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002; 106(25): 3143-421.
[http://dx.doi.org/10.1161/circ.106.25.3143] [PMID: 12485966]
[20]
Amiri M, Ramezani Tehrani F, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Risk of hypertension in women with polycystic ovary syndrome: A systematic review, meta-analysis and meta-regression. Reprod Biol Endocrinol 2020; 18(1): 23.
[http://dx.doi.org/10.1186/s12958-020-00576-1] [PMID: 32183820]
[21]
Özkan S, Yılmaz ÖÇ, Yavuz B. Increased masked hypertension prevalence in patients with polycystic ovary syndrome (PCOS). Clin Exp Hypertens 1993; 42(8): 681-4.
[22]
Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: A systematic review and meta-analysis. Hum Reprod Update 2012; 18(6): 618-37.
[http://dx.doi.org/10.1093/humupd/dms030] [PMID: 22767467]
[23]
Yildiz BO. Polycystic ovary syndrome: Is obesity a symptom? Womens Health 2013; 9(6): 505-7.
[http://dx.doi.org/10.2217/WHE.13.53] [PMID: 24161302]
[24]
Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38(9): 1165-74.
[http://dx.doi.org/10.2337/diab.38.9.1165] [PMID: 2670645]
[25]
Osibogun O, Ogunmoroti O, Michos ED. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention. Trends Cardiovasc Med 2020; 30(7): 399-404.
[http://dx.doi.org/10.1016/j.tcm.2019.08.010] [PMID: 31519403]
[26]
Cree-Green M, Carreau AM, Rahat H, et al. Amino acid and fatty acid metabolomic profile during fasting and hyperinsulinemia in girls with polycystic ovarian syndrome. Am J Physiol Endocrinol Metab 2019; 316(5): E707-18.
[http://dx.doi.org/10.1152/ajpendo.00532.2018] [PMID: 30753112]
[27]
Herman R, Sikonja J, Jensterle M, Janez A, Dolzan V. Insulin metabolism in polycystic ovary syndrome: Secretion, signaling, and clearance. Int J Mol Sci 2023; 24(4): 3140.
[http://dx.doi.org/10.3390/ijms24043140] [PMID: 36834549]
[28]
Corbould A, Kim YB, Youngren JF, et al. Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab 2005; 288(5): E1047-54.
[http://dx.doi.org/10.1152/ajpendo.00361.2004] [PMID: 15613682]
[29]
Takayama S, White MF, Kahn CR. Phorbol ester-induced serine phosphorylation of the insulin receptor decreases its tyrosine kinase activity. J Biol Chem 1988; 263(7): 3440-7.
[http://dx.doi.org/10.1016/S0021-9258(18)69090-8] [PMID: 3125181]
[30]
Li M, Youngren JF, Dunaif A, et al. Decreased insulin receptor (IR) autophosphorylation in fibroblasts from patients with PCOS: Effects of serine kinase inhibitors and IR activators. J Clin Endocrinol Metab 2002; 87(9): 4088-93.
[http://dx.doi.org/10.1210/jc.2002-020363] [PMID: 12213853]
[31]
Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepto NK. Insulin resistance in polycystic ovary syndrome: A systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod 2016; 31(11): 2619-31.
[http://dx.doi.org/10.1093/humrep/dew243] [PMID: 27907900]
[32]
Stepto NK, Cassar S, Joham AE, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod 2013; 28(3): 777-84.
[http://dx.doi.org/10.1093/humrep/des463] [PMID: 23315061]
[33]
Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol 2013; 4: 37.
[http://dx.doi.org/10.3389/fendo.2013.00037] [PMID: 23542897]
[34]
Oh YS, Bae GD, Baek DJ, Park EY, Jun HS. Fatty acid-induced lipotoxicity in pancreatic beta-cells during development of type 2 diabetes. Front Endocrinol 2018; 9: 384.
[http://dx.doi.org/10.3389/fendo.2018.00384] [PMID: 30061862]
[35]
Muniyappa R, Montagnani M, Koh KK, Quon MJ. Cardiovascular actions of insulin. Endocr Rev 2007; 28(5): 463-91.
[http://dx.doi.org/10.1210/er.2007-0006] [PMID: 17525361]
[36]
Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the bene-ficial effect of metformin therapy. J Clin Endocrinol Metab 2001; 86(10): 4666-73.
[http://dx.doi.org/10.1210/jcem.86.10.7904] [PMID: 11600523]
[37]
Zhou MS, Wang A, Yu H. Link between insulin resistance and hypertension: What is the evidence from evolutionary biology? Diabetol Metab Syndr 2014; 6(1): 12.
[http://dx.doi.org/10.1186/1758-5996-6-12] [PMID: 24485020]
[38]
Muniyappa R, Iantorno M, Quon MJ. An integrated view of insulin resistance and endothelial dysfunction. Endocrinol Metab Clin North Am 2008; 37(3): 685-711. ix-x.
[http://dx.doi.org/10.1016/j.ecl.2008.06.001] [PMID: 18775359]
[39]
Yang R, Yang S, Li R, Liu P, Qiao J, Zhang Y. Effects of hyperandrogenism on metabolic abnormalities in patients with polycystic ovary syndrome: A meta-analysis. Reprod Biol Endocrinol 2016; 14(1): 67.
[http://dx.doi.org/10.1186/s12958-016-0203-8] [PMID: 27756332]
[40]
Schiffer L, Kempegowda P, Arlt W, O’Reilly MW. MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease. Eur J Endocrinol 2017; 177(3): R125-43.
[http://dx.doi.org/10.1530/EJE-17-0124] [PMID: 28566439]
[41]
Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001; 103(10): 1410-5.
[http://dx.doi.org/10.1161/01.CIR.103.10.1410] [PMID: 11245645]
[42]
Mather KJ, Verma S, Corenblum B, Anderson TJ. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85(5): 1851-6.
[http://dx.doi.org/10.1210/jc.85.5.1851] [PMID: 10843164]
[43]
Sun D, Wu Y, Ding M, Zhu F. Comprehensive meta-analysis of functional and structural markers of subclinical atherosclerosis in women with polycystic ovary syndrome. Angiology 2022; 73(7): 622-34.
[http://dx.doi.org/10.1177/00033197211072598] [PMID: 35258380]
[44]
Osibogun O, Ogunmoroti O, Kolade OB, Hays AG, Okunrintemi V, Minhas AS, et al. A systematic review and meta-analysis of the association between polycystic ovary syndrome and coronary artery calcification. J Womens Health 2002; 31(6): 762-71.
[45]
Luque-Ramírez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF. Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum Reprod 2007; 22(12): 3197-203.
[http://dx.doi.org/10.1093/humrep/dem324] [PMID: 17933750]
[46]
Demir B, Pasa S, Demir S, et al. Morphologic and functional vascular alterations in patients with polycystic ovary syndrome. Clin Exp Obstet Gynecol 2011; 38(4): 401-4.
[PMID: 22268285]
[47]
Lakhani K, Hardiman P, Seifalian AM. Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis 2004; 175(2): 353-9.
[http://dx.doi.org/10.1016/j.atherosclerosis.2004.04.007] [PMID: 15262192]
[48]
Kelly CJG, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JMC. Altered vascular function in young women with polycystic ovary syn-drome. J Clin Endocrinol Metab 2002; 87(2): 742-6.
[http://dx.doi.org/10.1210/jcem.87.2.8199] [PMID: 11836314]
[49]
Meun C, Gunning MN, Louwers YV, et al. The cardiovascular risk profile of middle‐aged women with polycystic ovary syndrome. Clin Endocrinol 2020; 92(2): 150-8.
[http://dx.doi.org/10.1111/cen.14117] [PMID: 31638273]
[50]
Morgan CL, Jenkins-Jones S, Currie CJ, Rees DA. Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: A retrospective, observational study. J Clin Endocrinol Metab 2012; 97(9): 3251-60.
[http://dx.doi.org/10.1210/jc.2012-1690] [PMID: 22767635]
[51]
Chang AY, Ayers C, Minhajuddin A, et al. Polycystic ovarian syndrome and subclinical atherosclerosis among women of reproductive age in the Dallas heart study. Clin Endocrinol 2011; 74(1): 89-96.
[http://dx.doi.org/10.1111/j.1365-2265.2010.03907.x] [PMID: 21044112]
[52]
Iftikhar S, Collazo-Clavell ML, Roger VL, et al. Risk of cardiovascular events in patients with polycystic ovary syndrome. Neth J Med 2012; 70(2): 74-80.
[PMID: 22418753]
[53]
Zhou Y, Wang X, Jiang Y, et al. Association between polycystic ovary syndrome and the risk of stroke and all-cause mortality: Insights from a meta-analysis. Gynecol Endocrinol 2017; 33(12): 904-10.
[http://dx.doi.org/10.1080/09513590.2017.1347779] [PMID: 28696807]
[54]
Zhao L, Zhu Z, Lou H, et al. Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): A meta-analysis. Oncotarget 2016; 7(23): 33715-21.
[http://dx.doi.org/10.18632/oncotarget.9553] [PMID: 27220885]
[55]
Zhang J, Xu JH, Qu QQ, Zhong GQ. Risk of cardiovascular and cerebrovascular events in polycystic ovarian syndrome women: A meta-analysis of cohort studies. Front Cardiovasc Med 2020; 7: 552421.
[http://dx.doi.org/10.3389/fcvm.2020.552421] [PMID: 33282917]
[56]
Ollila MM, Arffman RK, Korhonen E, et al. Women with PCOS have an increased risk for cardiovascular disease regardless of diagnostic criteria: A prospective population-based cohort study. Eur J Endocrinol 2023; 189(1): 96-105.
[http://dx.doi.org/10.1093/ejendo/lvad077] [PMID: 37436934]
[57]
Lo ACQ, Lo CCW, Oliver-Williams C. Cardiovascular disease risk in women with hyperandrogenism, oligomenorrhea/menstrual irregularity or polycystic ovaries (components of polycystic ovary syndrome): A systematic review and meta-analysis. Eur Heart J Open 2023; 3(4): oead061.
[58]
Dwivedi AK, Vishwakarma D, Dubey P, Reddy S. Association of polycystic ovary syndrome with cardiovascular disease among female hospitalizations in the United States. Eur J Endocrinol 2023; 188(6): 555-63.
[http://dx.doi.org/10.1093/ejendo/lvad067] [PMID: 37307574]
[59]
Wekker V, van Dammen L, Koning A, et al. Long-term cardiometabolic disease risk in women with PCOS: A systematic review and meta-analysis. Hum Reprod Update 2020; 26(6): 942-60.
[http://dx.doi.org/10.1093/humupd/dmaa029] [PMID: 32995872]
[60]
Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: A retrospective cohort study. Clin Endocrinol 2000; 52(5): 595-600.
[http://dx.doi.org/10.1046/j.1365-2265.2000.01000.x] [PMID: 10792339]
[61]
Mani H, Levy MJ, Davies MJ, et al. Diabetes and cardiovascular events in women with polycystic ovary syndrome: A 20-year retrospective cohort study. Clin Endocrinol 2013; 78(6): 926-34.
[http://dx.doi.org/10.1111/cen.12068] [PMID: 23046078]
[62]
de Groot PCM, Dekkers OM, Romijn JA, Dieben SWM, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: A systematic review and meta-analysis. Hum Reprod Update 2011; 17(4): 495-500.
[http://dx.doi.org/10.1093/humupd/dmr001] [PMID: 21335359]
[63]
Glintborg D, Rubin KH, Nybo M, Abrahamsen B, Andersen M. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. Cardiovasc Diabetol 2018; 17(1): 37.
[http://dx.doi.org/10.1186/s12933-018-0680-5] [PMID: 29519249]
[64]
Hart R, Doherty DA. The potential implications of a PCOS diagnosis on a woman’s long-term health using data linkage. J Clin Endocrinol Metab 2015; 100(3): 911-9.
[http://dx.doi.org/10.1210/jc.2014-3886] [PMID: 25532045]
[65]
Solomon CG, Hu FB, Dunaif A, et al. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002; 87(5): 2013-7.
[http://dx.doi.org/10.1210/jcem.87.5.8471] [PMID: 11994334]
[66]
Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: Results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93(4): 1276-84.
[http://dx.doi.org/10.1210/jc.2007-0425] [PMID: 18182456]
[67]
Krentz AJ, von Mühlen D, Barrett-Connor E. Searching for polycystic ovary syndrome in postmenopausal women: Evidence of a dose-effect association with prevalent cardiovascular disease. Menopause 2007; 14(2): 284-92.
[http://dx.doi.org/10.1097/GME.0b013e31802cc7ab]
[68]
Merz CNB, Shaw LJ, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, et al. Cardiovascular disease and 10-year mortality in postmenopausal women with clinical features of polycystic ovary syndrome. J Womens Health 2002; 25(9): 875-81.
[69]
Berni TR, Morgan CL, Rees DA. Women with polycystic ovary syndrome have an increased risk of major cardiovascular events: A population study. J Clin Endocrinol Metab 2021; 106(9): e3369-80.
[http://dx.doi.org/10.1210/clinem/dgab392] [PMID: 34061968]
[70]
Dogan MI, Tasci I, Bulucu F, et al. Abdominal obesity is associated with a lower ankle-brachial index in women with polycystic ovary syndrome. Angiology 2013; 64(2): 105-11.
[http://dx.doi.org/10.1177/0003319711436248] [PMID: 22355193]
[71]
Schmidt J, Landin-Wilhelmsen K, Brännström M, Dahlgren E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: A 21-year controlled follow-up study. J Clin Endocrinol Metab 2011; 96(12): 3794-803.
[http://dx.doi.org/10.1210/jc.2011-1677] [PMID: 21956415]
[72]
Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998; 51(7): 581-6.
[http://dx.doi.org/10.1016/S0895-4356(98)00035-3] [PMID: 9674665]
[73]
Millán-de-Meer M, Luque-Ramírez M, Nattero-Chávez L, Escobar-Morreale HF. PCOS during the menopausal transition and after meno-pause: A systematic review and meta-analysis. Hum Reprod Update 2023; dmad015.
[http://dx.doi.org/10.1093/humupd/dmad015] [PMID: 37353908]
[74]
Day FR, Hinds DA, Tung JY, et al. Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome. Nat Commun 2015; 6(1): 8464.
[http://dx.doi.org/10.1038/ncomms9464] [PMID: 26416764]
[75]
Laven JSE, Visser JA, Uitterlinden AG, Vermeij WP, Hoeijmakers JHJ. Menopause: Genome stability as new paradigm. Maturitas 2016; 92: 15-23.
[http://dx.doi.org/10.1016/j.maturitas.2016.07.006] [PMID: 27621233]
[76]
Krysiak R, Okopień B, Gdula-Dymek A, Herman ZS. Update on the management of polycystic ovary syndrome. Pharmacol Rep 2006; 58(5): 614-25.
[PMID: 17085853]
[77]
Jensterle M, Herman R, Janež A. Therapeutic potential of glucagon-like peptide-1 agonists in polycystic ovary syndrome: From current clini-cal evidence to future perspectives. Biomedicines 2022; 10(8): 1989.
[http://dx.doi.org/10.3390/biomedicines10081989] [PMID: 36009535]
[78]
Lim SS, Hutchison SK, Van Ryswyk E, Norman RJ, Teede HJ, Moran LJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Libr 2019; 2019(3): CD007506.
[http://dx.doi.org/10.1002/14651858.CD007506.pub4] [PMID: 30921477]
[79]
Kite C, Lahart IM, Afzal I, et al. Exercise, or exercise and diet for the management of polycystic ovary syndrome: A systematic review and meta-analysis. Syst Rev 2019; 8(1): 51.
[http://dx.doi.org/10.1186/s13643-019-0962-3] [PMID: 30755271]
[80]
Abdalla MA, Shah N, Deshmukh H, et al. Impact of metformin on the clinical and metabolic parameters of women with polycystic ovary syndrome: A systematic review and meta-analysis of randomised controlled trials. Ther Adv Endocrinol Metab 2022; 13.
[http://dx.doi.org/10.1177/20420188221127142] [PMID: 36225721]
[81]
Miao K, Zhou H. Effect of statins combined or not combined with metformin on polycystic ovary syndrome: A systematic review and meta‐analysis. J Obstet Gynaecol Res 2022; 48(7): 1806-15.
[http://dx.doi.org/10.1111/jog.15301] [PMID: 35620917]
[82]
Cena H, Chiovato L, Nappi RE. Obesity, polycystic ovary syndrome, and infertility: A new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab 2020; 105(8): e2695-709.
[http://dx.doi.org/10.1210/clinem/dgaa285] [PMID: 32442310]
[83]
Wang FF, Wu Y, Zhu YH, et al. Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: A systematic review and network meta-analysis. Obes Rev 2018; 19(10): 1424-45.
[http://dx.doi.org/10.1111/obr.12720] [PMID: 30066361]
[84]
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375(4): 311-22.
[http://dx.doi.org/10.1056/NEJMoa1603827] [PMID: 27295427]
[85]
Kahal H, Aburima A, Ungvari T, et al. The effects of treatment with liraglutide on atherothrombotic risk in obese young women with poly-cystic ovary syndrome and controls. BMC Endocr Disord 2015; 15(1): 14.
[http://dx.doi.org/10.1186/s12902-015-0005-6] [PMID: 25880805]
[86]
Nylander M, Frøssing S, Kistorp C, Faber J, Skouby SO. Liraglutide in polycystic ovary syndrome: A randomized trial, investigating effects on thrombogenic potential. Endocr Connect 2017; 6(2): 89-99.
[http://dx.doi.org/10.1530/EC-16-0113] [PMID: 28119323]
[87]
Dawson AJ, Sathyapalan T, Vince R, et al. The effect of exenatide on cardiovascular risk markers in women with polycystic ovary syn-drome. Front Endocrinol 2019; 10: 189.
[http://dx.doi.org/10.3389/fendo.2019.00189] [PMID: 31001199]
[88]
Papadakis G, Kandaraki E, Papalou O, Vryonidou A, Diamanti-Kandarakis E. Is cardiovascular risk in women with PCOS a real risk? Current insights. Minerva Endocrinol 2017; 42(4): 340-55.
[PMID: 28146139]
[89]
Srivastava G, Apovian C. Future pharmacotherapy for obesity: New anti-obesity drugs on the horizon. Curr Obes Rep 2018; 7(2): 147-61.
[http://dx.doi.org/10.1007/s13679-018-0300-4] [PMID: 29504049]
[90]
Poredoš P, Schernthaner GH, Blinc A, et al. Endocrine disorders and peripheral arterial disease: A series of reviews. Curr Vasc Pharmacol 2023; 21(3): 147-8.
[http://dx.doi.org/10.2174/1570161121666230516141319] [PMID: 37194233]